top of page

Conclusion and Significance

  • A model of the maternal-fetal interface in the villous tree of the human placenta developed

  • Optimal ECM

    • The ECM we used promoted JEG3 cell adhesion

  • Immunofluorescent staining

    • Bioprinted model is similar to second trimester placenta stains

  • Anticipated diffusion

    • IgG, hCG, and glucose concentration levels across human placenta predicted based on published literature

 

Our preliminary trials can be used to successfully model the human placenta.

The majority of drugs are not tested on pregnant women due to ethical concerns, thus limiting groups of women from receiving treatment if needed due to unknown side effects on both developing child and carrying mother. Our model will provide a means of understanding the drug transport and diffusion which would occur in vivo, without human testing.

Through bioprinting a model of the human placenta, doctors, pharmaceutical, and clinicians will have the ability to understand the effects of the drug on the patients. If the developing child is in need of treatment, the drug must be able to successfully transport through the placental barrier without harming the pregnant mother and if the expecting mother is in need of treatment, the drug would be ideally unable to pass through the placental barrier. 

Successful pregnany is a healthy pregnancy.

 

Choose the ethical testing platform, an in vitro model of the human placenta.

bottom of page